Author:
Wilking Ulla,Karlsson Eva,Skoog Lambert,Hatschek Thomas,Lidbrink Elisabet,Elmberger Goran,Johansson Hemming,Lindström Linda,Bergh Jonas
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ross SJ, Fletcher JA, Linette GP (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325
2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235(4785):177–182
3. Slamon DJ, Leyland-Jones B, Shalk S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2/neu/NEU for metastatic breast cancer that overexpresses HER2/neu/NEU. N Engl J Med 44(11):783–792
4. Marty M, Cognetti F, Maraninchi D et al (2001) Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 9: 4265–4274
5. Slamon D, Eiermann W, Robert N, Pienowski T, Martin M, Rolski J et al (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. SABCS (abstract 62)
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献